MedTrace Logo

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2026-04-15

No results posted yet for this study

Summary

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Conditions

  • Myeloproliferative Neoplasms

Interventions

DRUG

INCA036978

INCA036978 will be administered at protocol defined dose.

DRUG

Standard disease-directed therapy

A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

Sponsors & Collaborators

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-27
Primary Completion
2030-05-24
Completion
2030-05-24
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07441694 on ClinicalTrials.gov